Paul A. Mahon Sells 11,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Price Performance

Shares of UTHR opened at $279.69 on Wednesday. The company’s 50-day moving average is $328.54 and its 200-day moving average is $353.09. The firm has a market capitalization of $12.56 billion, a PE ratio of 12.28, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the prior year, the firm earned $4.36 EPS. Analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the 4th quarter valued at $25,000. Dunhill Financial LLC boosted its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming acquired a new position in shares of United Therapeutics in the fourth quarter valued at about $62,000. Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at about $67,000. Finally, MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on UTHR shares. HC Wainwright restated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.